CRC
Certain mutations in tumor-suppressor genes are crucial biological triggers for CRC, with 80% of patients carrying common mutations in these genes.17
In metastatic CRC, patients who have mutations in the RAS family, mutations in BRAF, or MSI-H status have poor survival rates and shorter time to recurrence.18
Biomarkers targeting these mutations help with accurate and early detection of CRC, monitoring of treatment, and development of precision therapy.18